FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Vet Sci / Prospective Case Series of Clinical Signs and Adrenocorticot...
Veterinary sciences2022; 9(10); 572; doi: 10.3390/vetsci9100572

Prospective Case Series of Clinical Signs and Adrenocorticotrophin (ACTH) Concentrations in Seven Horses Transitioning to Pituitary Pars Intermedia Dysfunction (PPID).

Abstract: Poor recognition of subtle clinical abnormalities and equivocal ACTH concentrations make early diagnosis of PPID difficult. Progressive clinical findings and corresponding ACTH concentrations in horses transitioning to PPID over time have not been documented. Seven horses with ACTH concentrations equivocal for PPID (utilizing locally derived, seasonally adjusted diagnostic-cut off values (DCOV)) and no clinical signs of PPID were selected. Sequential measurement of basal and thyrotropin-releasing hormone (TRH)-stimulated ACTH concentrations and recording of clinical findings occurred from October 2017 to November 2021 in a prospective case series. In two horses, marked hypertrichosis developed. Although 1/11 basal ACTH concentrations were below DCOV in 2018, subsequently all basal ACTH concentrations in these two horses without treatment were greater than DCOV. One horse was treated with pergolide which normalized basal ACTH concentrations. Four horses developed intermittent, mild hypertrichosis, and one horse never developed hypertrichosis. Basal ACTH concentrations in these five horses were greater than DCOV in 63/133 (47.4%) of testing points. TRH-stimulated ACTH concentrations in these five horses were greater than DCOV in 77/133 (57.9%) of testing points, sometimes markedly increased and greater than the assay upper limit of detection (LoD) of 1250pg/mL. TRH-stimulated ACTH concentrations were most frequently positive in late summer and early autumn, with 24/37 (64.9%) of TRH-stimulated ACTH concentrations greater than the DCOV in February and March. Horses transitioning to PPID can have subtle clinical signs and equivocal ACTH concentrations. However, TRH-stimulated ACTH concentrations can be markedly greater than DCOV, especially in late summer and early autumn (February and March) allowing for identification of subclinical and transitional cases.
Get Full Text
Publication Date: 2022-10-17 PubMed ID: 36288186PubMed Central: PMC9607114DOI: 10.3390/vetsci9100572Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research article investigates the progression of clinical signs and adrenocorticotropin (ACTH) concentrations in seven horses potentially developing Pituitary Pars Intermedia Dysfunction (PPID). The research, conducted from October 2017 to November 2021, notes that early diagnosis is difficult due to slight clinical abnormalities and equivocal ACTH concentrations. The study provides in-depth insight into the symptoms and ACTH concentration changes in horses transitioning to PPID.

Research Methodology

  • The study selected seven horses that had ACTH concentrations on the borderline of PPID, calculated using locally adapted, seasonally adjusted diagnostic cut-off values (DCOV). The selected horses did not display clear signs of PPID initially.
  • The researchers performed sequential measurement of basal (natural) and thyrotropin-releasing hormone (TRH) stimulated ACTH concentrations over the course of four years. Along with this, they recorded clinical findings to keep track of the development of other symptoms.

Research Findings

  • Out of the seven horses, two developed significant hypertrichosis (excessive hair growth), a symptom associated with PPID. Though their basal ACTH concentrations in 2018 were below the DCOV, subsequent tests showed a continuous increase in ACTH levels, even without any treatment.
  • One of these two horses was treated with a drug called pergolide, which brought the ACTH concentrations back to normal ranges.
  • Four of the remaining five horses displayed mild, intermittent hypertrichosis while the ACTH concentrations in these horses exceeded the DCOV in nearly half of the tests performed.
  • The final horse didn’t display hypertrichosis and the ACTH measures were relatively unchanged.
  • However, when ACTH concentrations were induced with TRH, the ACTH values for these five horses were significantly above DCOV and sometimes exceeded the maximum limit of detection for the tests. This reaction was most frequent in late summer and early autumn, or specifically in February and March.

Conclusion

  • This study highlighted that horses transitioning to PPID may display subtle clinical signs and show ACTH concentrations around the borderline of PPID.
  • Interestingly, by stimulating ACTH concentrations using TRH, the ACTH levels can often significantly surpass the DCOV. This method proves particularly useful for detection in late summer and early autumn, aiding in the identification of cases in the early or subclinical stages.

Cite This Article

APA
Kirkwood NC, Hughes KJ, Stewart AJ. (2022). Prospective Case Series of Clinical Signs and Adrenocorticotrophin (ACTH) Concentrations in Seven Horses Transitioning to Pituitary Pars Intermedia Dysfunction (PPID). Vet Sci, 9(10), 572. https://doi.org/10.3390/vetsci9100572

Publication

Veterinary sciences
ISSN: 2306-7381
NlmUniqueID: 101680127
Country: Switzerland
Language: English
Volume: 9
Issue: 10
PII: 572

Researcher Affiliations

Kirkwood, Naomi C
  • School of Agricultural, Environmental and Veterinary Sciences, Charles Sturt University, Wagga Wagga, NSW 2678, Australia.
Hughes, Kristopher J
  • School of Agricultural, Environmental and Veterinary Sciences, Charles Sturt University, Wagga Wagga, NSW 2678, Australia.
Stewart, Allison J
  • School of Veterinary Science, Gatton Campus, The University of Queensland, Gatton, QLD 4343, Australia.

Conflict of Interest Statement

The authors declare no conflict of interest.

References

This article includes 67 references
  1. Durham A, McGowan C, Fey K, Tamzali Y, Van der Kolk J. Pituitary pars intermedia dysfunction: Diagnosis and treatment. Equine Vet. Educ. 2014;26:216–223.
    doi: 10.1111/eve.12160google scholar: lookup
  2. Horn R, Stewart AJ, Jackson KV, Dryburgh EL, Medina-Torres CE, Bertin FR. Clinical implications of using adrenocorticotropic hormone diagnostic cutoffs or reference intervals to diagnose pituitary pars intermedia dysfunction in mature horses.. J Vet Intern Med 2021 Jan;35(1):560-570.
    doi: 10.1111/jvim.16017pmc: PMC7848300pubmed: 33368633google scholar: lookup
  3. Ireland JL, McGowan CM. Epidemiology of pituitary pars intermedia dysfunction: A systematic literature review of clinical presentation, disease prevalence and risk factors.. Vet J 2018 May;235:22-33.
    doi: 10.1016/j.tvjl.2018.03.002pubmed: 29704935google scholar: lookup
  4. McGowan TW, Pinchbeck GP, McGowan CM. Prevalence, risk factors and clinical signs predictive for equine pituitary pars intermedia dysfunction in aged horses.. Equine Vet J 2013 Jan;45(1):74-9.
    doi: 10.1111/j.2042-3306.2012.00578.xpubmed: 22594955google scholar: lookup
  5. Kirkwood NC, Hughes KJ, Stewart AJ. Pituitary Pars Intermedia Dysfunction (PPID) in Horses.. Vet Sci 2022 Oct 10;9(10).
    doi: 10.3390/vetsci9100556pmc: PMC9611634pubmed: 36288169google scholar: lookup
  6. Fortin JS, Hetak AA, Duggan KE, Burglass CM, Penticoff HB, Schott HC 2nd. Equine pituitary pars intermedia dysfunction: a spontaneous model of synucleinopathy.. Sci Rep 2021 Aug 6;11(1):16036.
    doi: 10.1038/s41598-021-95396-7pmc: PMC8346493pubmed: 34362943google scholar: lookup
  7. McFarlane D, Cribb AE. Systemic and pituitary pars intermedia antioxidant capacity associated with pars intermedia oxidative stress and dysfunction in horses.. Am J Vet Res 2005 Dec;66(12):2065-72.
    doi: 10.2460/ajvr.2005.66.2065pubmed: 16379648google scholar: lookup
  8. Huang L, Palmieri C, Bertin FR. Correlation of pituitary histomorphometry with dopamine and dopamine D2 receptor expression in horses with pituitary pars intermedia dysfunction.. Res Vet Sci 2022 Dec 20;152:427-433.
    doi: 10.1016/j.rvsc.2022.08.018pubmed: 36126509google scholar: lookup
  9. Carmalt JL, Mortazavi S, McOnie RC, Allen AL, Unniappan S. Profiles of pro-opiomelanocortin and encoded peptides, and their processing enzymes in equine pituitary pars intermedia dysfunction.. PLoS One 2018;13(1):e0190796.
    doi: 10.1371/journal.pone.0190796pmc: PMC5757946pubmed: 29309431google scholar: lookup
  10. Heinrichs M, Baumgärtner W, Capen CC. Immunocytochemical demonstration of proopiomelanocortin-derived peptides in pituitary adenomas of the pars intermedia in horses.. Vet Pathol 1990 Nov;27(6):419-25.
    doi: 10.1177/030098589902700606pubmed: 2177580google scholar: lookup
  11. Orth DN, Holscher MA, Wilson MG, Nicholson WE, Plue RE, Mount CD. Equine Cushing's disease: plasma immunoreactive proopiolipomelanocortin peptide and cortisol levels basally and in response to diagnostic tests.. Endocrinology 1982 Apr;110(4):1430-41.
    doi: 10.1210/endo-110-4-1430pubmed: 6277607google scholar: lookup
  12. Wilson MG, Nicholson WE, Holscher MA, Sherrell BJ, Mount CD, Orth DN. Proopiolipomelanocortin peptides in normal pituitary, pituitary tumor, and plasma of normal and Cushing's horses.. Endocrinology 1982 Mar;110(3):941-54.
    doi: 10.1210/endo-110-3-941pubmed: 6276164google scholar: lookup
  13. Yoshikawa H, Oishi H, Sumi A, Ueki H, Oyamada T, Yoshikawa T. Spontaneous Pituitary Adenomas of the Pars Intermedia in 5 Aged Horses: Histopathological, Immunohistochemical and Ultrastructural Studies. J. Equine Sci. 2001;12:119–126.
    doi: 10.1294/jes.12.119google scholar: lookup
  14. Horn R, Bamford NJ, Afonso T, Sutherland M, Buckerfield J, Tan RHH, Secombe CJ, Stewart AJ, Bertin FR. Factors associated with survival, laminitis and insulin dysregulation in horses diagnosed with equine pituitary pars intermedia dysfunction.. Equine Vet J 2019 Jul;51(4):440-445.
    doi: 10.1111/evj.13041pubmed: 30417404google scholar: lookup
  15. Rohrbach BW, Stafford JR, Clermont RS, Reed SM, Schott HC 2nd, Andrews FM. Diagnostic frequency, response to therapy, and long-term prognosis among horses and ponies with pituitary par intermedia dysfunction, 1993-2004.. J Vet Intern Med 2012 Jul-Aug;26(4):1027-34.
    doi: 10.1111/j.1939-1676.2012.00932.xpubmed: 22524260google scholar: lookup
  16. Miller MA, Pardo ID, Jackson LP, Moore GE, Sojka JE. Correlation of pituitary histomorphometry with adrenocorticotrophic hormone response to domperidone administration in the diagnosis of equine pituitary pars intermedia dysfunction.. Vet Pathol 2008 Jan;45(1):26-38.
    doi: 10.1354/vp.45-1-26pubmed: 18192571google scholar: lookup
  17. Beech J, Boston R, Lindborg S, Russell GE. Adrenocorticotropin concentration following administration of thyrotropin-releasing hormone in healthy horses and those with pituitary pars intermedia dysfunction and pituitary gland hyperplasia.. J Am Vet Med Assoc 2007 Aug 1;231(3):417-26.
    doi: 10.2460/javma.231.3.417pubmed: 17669045google scholar: lookup
  18. Carmalt JL, Waldner CL, Allen AL. Equine pituitary pars intermedia dysfunction: An international survey of veterinarians' approach to diagnosis, management, and estimated prevalence.. Can J Vet Res 2017 Oct;81(4):261-269.
    pmc: PMC5644449pubmed: 29081583
  19. Toribio RE. Diagnosing equine pars intermedia dysfunction: are we there yet?. J Vet Intern Med 2005 Mar-Apr;19(2):145-6.
    doi: 10.1111/j.1939-1676.2005.tb02674.xpubmed: 15822556google scholar: lookup
  20. Frank N, Andrews FM, Sommardahl CS, Eiler H, Rohrbach BW, Donnell RL. Evaluation of the combined dexamethasone suppression/ thyrotropin-releasing hormone stimulation test for detection of pars intermedia pituitary adenomas in horses.. J Vet Intern Med 2006 Jul-Aug;20(4):987-93.
    doi: 10.1111/j.1939-1676.2006.tb01816.xpubmed: 16955827google scholar: lookup
  21. van der Kolk JH, Wensing T, Kalsbeek HC, Breukink HJ. Laboratory diagnosis of equine pituitary pars intermedia adenoma.. Domest Anim Endocrinol 1995 Jan;12(1):35-9.
    doi: 10.1016/0739-7240(94)00006-Mpubmed: 7621678google scholar: lookup
  22. Hart K, Durham A, Frank N, McGowan C, Schott H, Stewart AJ. EEG Recommendations on Diagnosis and Management of Pituitary Pars Intermedia Dysfunction (PPID). .
  23. Schreiber CM, Stewart AJ, Kwessi E, Behrend EN, Wright JC, Kemppainen RJ, Busch KA. Seasonal variation in results of diagnostic tests for pituitary pars intermedia dysfunction in older, clinically normal geldings.. J Am Vet Med Assoc 2012 Jul 15;241(2):241-8.
    doi: 10.2460/javma.241.2.241pubmed: 22765372google scholar: lookup
  24. Mc Gowan TW, Pinchbeck GP, Mc Gowan CM. Evaluation of basal plasma α-melanocyte-stimulating hormone and adrenocorticotrophic hormone concentrations for the diagnosis of pituitary pars intermedia dysfunction from a population of aged horses.. Equine Vet J 2013 Jan;45(1):66-73.
    doi: 10.1111/j.2042-3306.2012.00575.xpubmed: 22563728google scholar: lookup
  25. Durham AE, Clarke BR, Potier JFN, Hammarstrand R, Malone GL. Clinically and temporally specific diagnostic thresholds for plasma ACTH in the horse.. Equine Vet J 2021 Mar;53(2):250-260.
    doi: 10.1111/evj.13292pubmed: 32470177google scholar: lookup
  26. Horn R, Bertin FR. Evaluation of combined testing to simultaneously diagnose pituitary pars intermedia dysfunction and insulin dysregulation in horses.. J Vet Intern Med 2019 Sep;33(5):2249-2256.
    doi: 10.1111/jvim.15617pmc: PMC6766519pubmed: 31498947google scholar: lookup
  27. Frank N. Pituitary pars intermedia dysfunction. In: Robinson N.E., Sprayberry K.A., editors. Robinson’s Current Therapy in Equine Medicine. 7th ed. Elsevier Inc.; Maryland Heights, MO, USA: 2015. pp. 574–577.
  28. Funk RA, Stewart AJ, Wooldridge AA, Kwessi E, Kemppainen RJ, Behrend EN, Zhong Q, Johnson AK. Seasonal changes in plasma adrenocorticotropic hormone and α-melanocyte-stimulating hormone in response to thyrotropin-releasing hormone in normal, aged horses.. J Vet Intern Med 2011 May-Jun;25(3):579-85.
    doi: 10.1111/j.1939-1676.2011.0712.xpubmed: 21457320google scholar: lookup
  29. Copas VE, Durham AE. Circannual variation in plasma adrenocorticotropic hormone concentrations in the UK in normal horses and ponies, and those with pituitary pars intermedia dysfunction.. Equine Vet J 2012 Jul;44(4):440-3.
    doi: 10.1111/j.2042-3306.2011.00444.xpubmed: 21848531google scholar: lookup
  30. Secombe CJ, Bailey SR, de Laat MA, Hughes KJ, Stewart AJ, Sonis JM, Tan R. Equine pituitary pars intermedia dysfunction: current understanding and recommendations from the Australian and New Zealand Equine Endocrine Group.. Aust Vet J 2018 Jul;96(7):233-242.
    doi: 10.1111/avj.12716pubmed: 29862508google scholar: lookup
  31. Alexander SL, Irvine CH. The effect of social stress on adrenal axis activity in horses: the importance of monitoring corticosteroid-binding globulin capacity.. J Endocrinol 1998 Jun;157(3):425-32.
    doi: 10.1677/joe.0.1570425pubmed: 9691975google scholar: lookup
  32. Alexander SL, Irvine CH, Livesey JH, Donald RA. Effect of isolation stress on concentrations of arginine vasopressin, alpha-melanocyte-stimulating hormone and ACTH in the pituitary venous effluent of the normal horse.. J Endocrinol 1988 Mar;116(3):325-34.
    doi: 10.1677/joe.0.1160325pubmed: 2832503google scholar: lookup
  33. Alexander SL, Irvine CH, Ellis MJ, Donald RA. The effect of acute exercise on the secretion of corticotropin-releasing factor, arginine vasopressin, and adrenocorticotropin as measured in pituitary venous blood from the horse.. Endocrinology 1991 Jan;128(1):65-72.
    doi: 10.1210/endo-128-1-65pubmed: 1846116google scholar: lookup
  34. Jacob SI, Geor RJ, Weber PSD, Harris PA, McCue ME. Effect of dietary carbohydrates and time of year on ACTH and cortisol concentrations in adult and aged horses.. Domest Anim Endocrinol 2018 Apr;63:15-22.
    doi: 10.1016/j.domaniend.2017.10.005pubmed: 29195115google scholar: lookup
  35. Stewart AJ, Hackett E, Bertin FR, Towns TJ. Cortisol and adrenocorticotropic hormone concentrations in horses with systemic inflammatory response syndrome.. J Vet Intern Med 2019 Sep;33(5):2257-2266.
    doi: 10.1111/jvim.15620pmc: PMC6766528pubmed: 31512777google scholar: lookup
  36. Friedrichs KR, Harr KE, Freeman KP, Szladovits B, Walton RM, Barnhart KF, Blanco-Chavez J. ASVCP reference interval guidelines: determination of de novo reference intervals in veterinary species and other related topics.. Vet Clin Pathol 2012 Dec;41(4):441-53.
    doi: 10.1111/vcp.12006pubmed: 23240820google scholar: lookup
  37. Diez de Castro E, Lopez I, Cortes B, Pineda C, Garfia B, Aguilera-Tejero E. Influence of feeding status, time of the day, and season on baseline adrenocorticotropic hormone and the response to thyrotropin releasing hormone-stimulation test in healthy horses.. Domest Anim Endocrinol 2014 Jul;48:77-83.
    doi: 10.1016/j.domaniend.2014.02.004pubmed: 24906932google scholar: lookup
  38. Hu K, Stewart AJ, Yuen KY, Hinrichsen S, Dryburgh EL, Bertin FR. The effect of freeze-thaw cycles on determination of immunoreactive plasma adrenocorticotrophic hormone concentrations in horses.. J Vet Intern Med 2020 May;34(3):1350-1356.
    doi: 10.1111/jvim.15771pmc: PMC7255672pubmed: 32255541google scholar: lookup
  39. Kam YN, McKenzie K, Coyle M, Bertin FR. Repeatability of a thyrotropin-releasing hormone stimulation test for diagnosis of pituitary pars intermedia dysfunction in mature horses.. J Vet Intern Med 2021 Nov;35(6):2885-2890.
    doi: 10.1111/jvim.16281pmc: PMC8692209pubmed: 34642962google scholar: lookup
  40. Hinrichsen SL, Yuen KY, Dryburgh EL, Bertin FR, Stewart AJ. Short-Term Effects of Temperature and Thyrotropin-Releasing Hormone Stimulation on Adrenocorticotropin Stability in Horses.. Animals (Basel) 2022 Jan 28;12(3).
    doi: 10.3390/ani12030324pmc: PMC8833476pubmed: 35158648google scholar: lookup
  41. Byrne DP, Secombe CJ, Tan RHH, Perera DI, Watts SP, Wearn JG. Circannual variability in adrenocorticotropic hormone responses to administration of thyrotropin-releasing hormone in clinically normal horses in Australia.. Vet J 2018 Aug;238:58-62.
    doi: 10.1016/j.tvjl.2018.07.008pubmed: 30103916google scholar: lookup
  42. Frank N, Elliott SB, Chameroy KA, Tóth F, Chumbler NS, McClamroch R. Association of season and pasture grazing with blood hormone and metabolite concentrations in horses with presumed pituitary pars intermedia dysfunction.. J Vet Intern Med 2010 Sep-Oct;24(5):1167-75.
    doi: 10.1111/j.1939-1676.2010.0547.xpubmed: 20666984google scholar: lookup
  43. Irvine KL, Burt K, Hill AJ, Shaw S, Papasouliotis K. Initial analytic quality assessment and method comparison of an immunoassay for adrenocorticotropic hormone measurement in equine samples.. Vet Clin Pathol 2016 Mar;45(1):154-63.
    doi: 10.1111/vcp.12326pubmed: 26756538google scholar: lookup
  44. McFarlane D. Equine pituitary pars intermedia dysfunction.. Vet Clin North Am Equine Pract 2011 Apr;27(1):93-113.
    doi: 10.1016/j.cveq.2010.12.007pubmed: 21392656google scholar: lookup
  45. Couëtil L, Paradis MR, Knoll J. Plasma adrenocorticotropin concentration in healthy horses and in horses with clinical signs of hyperadrenocorticism.. J Vet Intern Med 1996 Jan-Feb;10(1):1-6.
    doi: 10.1111/j.1939-1676.1996.tb02016.xpubmed: 8965262google scholar: lookup
  46. Innerå M, Petersen AD, Desjardins DR, Steficek BA, Rosser EJ Jr, Schott HC 2nd. Comparison of hair follicle histology between horses with pituitary pars intermedia dysfunction and excessive hair growth and normal aged horses.. Vet Dermatol 2013 Feb;24(1):212-7.e46-7.
    doi: 10.1111/j.1365-3164.2012.01080.xpubmed: 23331700google scholar: lookup
  47. Brosnahan MM, Paradis MR. Demographic and clinical characteristics of geriatric horses: 467 cases (1989-1999).. J Am Vet Med Assoc 2003 Jul 1;223(1):93-8.
    doi: 10.2460/javma.2003.223.93pubmed: 12839071google scholar: lookup
  48. Mellor DJ, Love S, Walker R, Gettinby G, Reid SW. Sentinel practice-based survey of the management and health of horses in northern Britain.. Vet Rec 2001 Oct 6;149(14):417-23.
    doi: 10.1136/vr.149.14.417pubmed: 11678214google scholar: lookup
  49. McFarlane D, Hill K, Anton J. Neutrophil function in healthy aged horses and horses with pituitary dysfunction.. Vet Immunol Immunopathol 2015 Jun 15;165(3-4):99-106.
    doi: 10.1016/j.vetimm.2015.04.006pubmed: 25962580google scholar: lookup
  50. Hart KA, Kitchings KM, Kimura S, Norton NA, Myrna KE. Measurement of cortisol concentration in the tears of horses and ponies with pituitary pars intermedia dysfunction.. Am J Vet Res 2016 Nov;77(11):1236-1244.
    doi: 10.2460/ajvr.77.11.1236pubmed: 27805438google scholar: lookup
  51. Spelta CW, Axon JE. Case series of equine pituitary pars intermedia dysfunction in a tropical climate.. Aust Vet J 2012 Nov;90(11):451-6.
    doi: 10.1111/j.1751-0813.2012.00997.xpubmed: 23106327google scholar: lookup
  52. Schott HC 2nd. Pituitary pars intermedia dysfunction: equine Cushing's disease.. Vet Clin North Am Equine Pract 2002 Aug;18(2):237-70.
    doi: 10.1016/S0749-0739(02)00018-4pubmed: 15635907google scholar: lookup
  53. McFarlane D. Pathophysiology and clinical features of pituitary pars intermedia dysfunction. Equine Vet. Educ. 2014;26:592–598.
    doi: 10.1111/eve.12237google scholar: lookup
  54. Miller AB, Loynachan AT, Barker VD, Adams AA. Investigation of innate immune function in adult and geriatric horses.. Vet Immunol Immunopathol 2021 May;235:110207.
    doi: 10.1016/j.vetimm.2021.110207pubmed: 33735821google scholar: lookup
  55. Miller AB, Loynachan AT, Bush HM, Hart KA, Barker VD, Campana-Emard AG, Grubbs ST, Adams AA. Effects of pituitary pars intermedia dysfunction and Prascend (pergolide tablets) treatment on endocrine and immune function in horses.. Domest Anim Endocrinol 2021 Jan;74:106531.
    doi: 10.1016/j.domaniend.2020.106531pubmed: 32942194google scholar: lookup
  56. Miller C, Utter ML, Beech J. Evaluation of the effects of age and pituitary pars intermedia dysfunction on corneal sensitivity in horses.. Am J Vet Res 2013 Jul;74(7):1030-5.
    doi: 10.2460/ajvr.74.7.1030pubmed: 23802675google scholar: lookup
  57. Miller MA, Moore GE, Bertin FR, Kritchevsky JE. What's New in Old Horses? Postmortem Diagnoses in Mature and Aged Equids.. Vet Pathol 2016 Mar;53(2):390-8.
    doi: 10.1177/0300985815608674pubmed: 26459516google scholar: lookup
  58. Beech J, Boston R, Lindborg S. Comparison of cortisol and ACTH responses after administration of thyrotropin releasing hormone in normal horses and those with pituitary pars intermedia dysfunction.. J Vet Intern Med 2011 Nov-Dec;25(6):1431-8.
    doi: 10.1111/j.1939-1676.2011.00810.xpubmed: 22092639google scholar: lookup
  59. Thane K, Uricchio C, Frank N. Effect of early or late blood sampling on thyrotropin releasing hormone stimulation test results in horses.. J Vet Intern Med 2022 Mar;36(2):770-777.
    doi: 10.1111/jvim.16362pmc: PMC8965261pubmed: 35049089google scholar: lookup
  60. McGowan C. Hyperadrenocorticism (Pituitary Pars Intermedia Dysfunction) in Horses. 1st ed. John Wiley & Sons, Inc.; Hoboken, NJ, USA: 2013. pp. 100–114.
  61. Tatum RC, McGowan CM, Ireland JL. Efficacy of pergolide for the management of equine pituitary pars intermedia dysfunction: A systematic review.. Vet J 2020 Dec;266:105562.
    doi: 10.1016/j.tvjl.2020.105562pubmed: 33323174google scholar: lookup
  62. Donaldson MT, LaMonte BH, Morresey P, Smith G, Beech J. Treatment with pergolide or cyproheptadine of pituitary pars intermedia dysfunction (equine Cushing's disease).. J Vet Intern Med 2002 Nov-Dec;16(6):742-6.
    doi: 10.1892/0891-6640(2002)0162.3.co;2pubmed: 12465775google scholar: lookup
  63. Perkins GA, Lamb S, Erb HN, Schanbacher B, Nydam DV, Divers TJ. Plasma adrenocorticotropin (ACTH) concentrations and clinical response in horses treated for equine Cushing's disease with cyproheptadine or pergolide.. Equine Vet J 2002 Nov;34(7):679-85.
    doi: 10.2746/042516402776250333pubmed: 12455838google scholar: lookup
  64. Banse HE, Whitehead AE, McFarlane D, Chelikani PK. Markers of muscle atrophy and impact of treatment with pergolide in horses with pituitary pars intermedia dysfunction and muscle atrophy.. Domest Anim Endocrinol 2021 Jul;76:106620.
    doi: 10.1016/j.domaniend.2021.106620pubmed: 33740552google scholar: lookup
  65. Beech J, McFarlane D, Lindborg S, Sojka JE, Boston RC. α-Melanocyte--stimulating hormone and adrenocorticotropin concentrations in response to thyrotropin-releasing hormone and comparison with adrenocorticotropin concentration after domperidone administration in healthy horses and horses with pituitary pars intermedia dysfunction.. J Am Vet Med Assoc 2011 May 15;238(10):1305-15.
    doi: 10.2460/javma.238.10.1305pubmed: 21568777google scholar: lookup
  66. McFarlane D, Beech J, Cribb A. Alpha-melanocyte stimulating hormone release in response to thyrotropin releasing hormone in healthy horses, horses with pituitary pars intermedia dysfunction and equine pars intermedia explants.. Domest Anim Endocrinol 2006 May;30(4):276-88.
    doi: 10.1016/j.domaniend.2005.07.005pubmed: 16115743google scholar: lookup
  67. McFarlane D, Miller LM, Craig LE, Dybdal NO, Habecker PL, Miller MA, Patterson JS, Cribb AE. Agreement in histologic assessments of the pituitary pars intermedia in aged horses.. Am J Vet Res 2005 Dec;66(12):2055-9.
    doi: 10.2460/ajvr.2005.66.2055pubmed: 16379646google scholar: lookup

Citations

This article has been cited 3 times.
  1. Kirkwood NC, Hughes KJ, Stewart AJ. Pituitary Pars Intermedia Dysfunction (PPID) in Horses. Vet Sci 2022 Oct 10;9(10).
    doi: 10.3390/vetsci9100556pubmed: 36288169google scholar: lookup
  2. Goodrich EL, Llanos-Soto SG, Ivanek R, Pinn-Woodcock T, Frye E, Wells A, Purdy SR, Berryhill E, Place NJ. Both Season and Equid Type Affect Endogenous Adrenocorticotropic Hormone Concentrations in Healthy Donkeys, Mules and Hinnies in the United States. Animals (Basel) 2026 Jan 16;16(2).
    doi: 10.3390/ani16020290pubmed: 41594480google scholar: lookup
  3. Menzies-Gow NJ. Equine Pituitary Pars Intermedia Dysfunction. Vet Sci 2025 Aug 20;12(8).
    doi: 10.3390/vetsci12080780pubmed: 40872730google scholar: lookup
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.